Wells Fargo notes that shares of GeneDx (WGS) are trading lower after a short report was published this morning by Grizzly Research, adding ...
BTIG analysts stood firm on their positive stance towards GeneDx (NASDAQ:WGS), reiterating a Buy rating and a $95.00 price target for the company's stock. With analyst targets ranging from $70 to $118 ...
GAITHERSBURG, Md., January 28, 2025--GeneDx to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 18, 2025 STAMFORD, Conn., January 17, 2025--GeneDx Holdings Corp ...
GeneDx Holdings Corp. experienced a dramatic turnaround in 2024, achieving profitability and 100x returns, driven by reduced cash burn and strategic product innovations. Key growth catalysts ...
GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and ...
GeneDx (WGS) Holdings eported preliminary financial results for the fourth quarter and full year of 2024. “2024 was a transformative year for GeneDx, as we achieved our profitability milestone ...
“2024 was a transformative year for GeneDx, as we achieved our profitability milestone of adjusted net income, released landmark studies, strengthened our products and expanded our team to set ...
Adds analyst comment. GeneDX (NASDAQ:WGS) fell 4% after a short report from Grizzly Research on the genetic testing company. Grizzly Research disclosed that it's short shares of GeneDX (NASDAQ:WGS).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback